Advertisement
Original Study| Volume 21, ISSUE 2, P212-219, February 2020

Optimizing Practices, Use, Care and Services–Antipsychotics (OPUS-AP) in Long-term Care Centers in Québec, Canada: A Strategy for Best Practices

Published:October 25, 2019DOI:https://doi.org/10.1016/j.jamda.2019.08.027

      Abstract

      Objectives

      Antipsychotic medications are often used for the first-line management of behavioral and psychological symptoms of dementia (BPSD) contrary to guideline recommendations. The Optimizing Practices, Use, Care and Services–Antipsychotics (OPUS-AP) strategy aims to improve the well-being of long-term care (LTC) residents with major neurocognitive disorder (MNCD) by implementing a resident-centered approach, nonpharmacologic interventions, and antipsychotic deprescribing in inappropriate indications.

      Design

      Prospective, closed cohort supplemented by a developmental evaluation.

      Setting and Participants

      Residents of designated wards in 24 LTC centers in Québec, Canada.

      Methods

      Provincial guidelines were disseminated, followed by the implementation of an integrated knowledge translation and mobilization strategy, including training, coaching, clinical tools, evaluation of clinical practices, and a change management strategy. Antipsychotic, benzodiazepine, and antidepressant prescriptions; BPSD; and falls were evaluated every 3 months, for 9 months, from January to October 2018. Semistructured interviews (n = 20) were conducted with LTC teams to evaluate the implementation of OPUS-AP.

      Results

      Of 1054 residents, 78.3% had an MNCD diagnosis and 51.7% an antipsychotic prescription. The cohort included 464 residents with both MNCD and antipsychotic prescription. Antipsychotic deprescribing (cessation or dose decrease) was attempted in 220 of the 344 residents still admitted at 9 months. Complete cessation was observed in 116 of these residents (52.7%) and dose reduction in 72 (32.7%), for a total of 188 residents (85.5%; 95% confidence interval: 80.1%, 89.8%). A decrease in benzodiazepine prescriptions and improvements in Cohen-Mansfield Agitation Inventory scores were observed among residents who had their antipsychotics deprescribed. Caregivers and clinicians expressed satisfaction as a result of observing an improved quality of life among residents.

      Conclusions and Implications

      Antipsychotic deprescribing was successful in a vast majority of LTC residents with MNCD without worsening of BPSD. Based on this success, phase 2 of OPUS-AP is now under way in 129 LTC centers in Québec.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • 2019 American Geriatrics Society Beers Criteria Update Expert Panel
        American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.
        J Am Geriatr Soc. 2019; 67: 674-694
        • O’Mahony D.
        • O’Sullivan D.
        • Byrne S.
        • et al.
        STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2.
        Age Ageing. 2015; 44: 213-218
        • Rabins P.V.
        • Rovner B.W.
        • Rummans T.
        • et al.
        Guideline watch (October 2014): Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias.
        (Available at:)
        • Bjerre L.M.
        • Farrell B.
        • Hogel M.
        • et al.
        Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline.
        Can Fam Physician. 2018; 64: 17-27
        • Choosing Wisely Canada
        Toolkit: When psychosis isn’t the diagnosis.
        (Available at:)
      1. National Institute for Health and Care Excellence. Dementia: Assessment, management and support for people living with dementia and their carers. Available at: nice.org.uk/guidance/ng97. Accessed March 29, 2019.

        • Gurwitz J.H.
        • Bonner A.
        • Berwick D.M.
        Reducing excessive use of antipsychotic agents in nursing homes.
        JAMA. 2017; 318: 118-119
        • Kirkham J.
        • Sherman C.
        • Velkers C.
        • et al.
        Antipsychotic use in dementia.
        Can J Psychiatry. 2017; 62: 170-181
        • Macaulay M.S.
        Efforts to reduce antipsychotic use in dementia care are starting to bear fruit, but a lot of work remains to be done.
        J Am Med Dir Assoc. 2017; 18: 204-206
        • Szczepura A.
        • Wild D.
        • Khan A.J.
        • et al.
        Antipsychotic prescribing in care homes before and after launch of a national dementia strategy: An observational study in English institutions over a 4-year period.
        BMJ Open. 2016; 6: e009882
        • Morarescu E.
        Étude sur l’usage des antipsychotiques. Volet III: Personnes âgées de 25 ans ou plus, principalement celles de 65 ans ou plus avec un diagnostic de démence. Institut national d’excellence en santé et en services sociaux. 2012;8:1-70.
        (Available at:)
        • Canadian Foundation for Healthcare Improvement
        Appropriate use of antipsychotics.
        (Available at:)
        • Breton M.C.
        • Carpentier G.
        • Gernigon G.
        • et al.
        Usage optimal des antipsychotiques et la prise en charge non pharmacologique des symptômes comportementaux et psychologiques de la démence chez les personnes atteintes de troubles neurocognitifs majeurs qui résident en centre d’hébergement et de soins de longue durée.
        (Available at:)
        • Thompson Coon J.
        • Abbott R.
        • Rogers M.
        • et al.
        Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: A systematic review.
        J Am Med Dir Assoc. 2014; 15: 706-718
        • Harrison S.L.
        • Cations M.
        • Jessop T.
        • et al.
        Approaches to deprescribing psychotropic medications for changed behaviours in long-term care residents living with dementia.
        Drugs Aging. 2019; 36: 125-136
        • Cohen-Mansfield J.
        • Marx M.S.
        • Rosenthal A.S.
        A description of agitation in a nursing home.
        J Gerontol. 1989; 44: M77-M84
        • Cummings J.L.
        • Mega M.
        • Gray K.
        • et al.
        The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia.
        Neurology. 1994; 44: 2308-2314
        • Devanand D.P.
        • Mintzer J.
        • Schultz S.K.
        • et al.
        Relapse risk after discontinuation of risperidone in Alzheimer’s disease.
        N Engl J Med. 2012; 367: 1497-1507
        • Clopper C.J.
        • Pearson E.S.
        The use of confidence or fiducial limits illustrated in the case of the binomial.
        Biometrika. 1934; 26: 404-413
        • R Core Team (2019)
        R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
        (Available at:)
        www.R-project.org/
        Date accessed: March 16, 2019
        • Fagen M.C.
        • Redman S.D.
        • Stacks J.
        • et al.
        Developmental evaluation: Building innovations in complex environments.
        Health Promot Pract. 2011; 12: 645-650
        • Lennox L.
        • Doyle C.
        • Reed J.E.
        • et al.
        What makes a sustainability tool valuable, practical and useful in real-world healthcare practice? A mixed-methods study on the development of the Long Term Success Tool in Northwest London.
        BMJ Open. 2017; 7: e014417
        • Van Leeuwen E.
        • Petrovic M.
        • van Driel M.L.
        • et al.
        Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia.
        Cochrane Database Syst Rev. 2018; 3: CD007726
        • Brodaty H.
        • Aerts L.
        • Harrison F.
        • et al.
        Antipsychotic deprescription for older adults in long-term care: The HALT Study.
        J Am Med Dir Assoc. 2018; 19: 592-600.e7
        • Rios S.
        • Perlman C.M.
        • Costa A.
        • et al.
        Antipsychotics and dementia in Canada: A retrospective cross-sectional study of four health sectors.
        BMC Geriatr. 2017; 17: 244
        • Maust D.T.
        • Kim H.M.
        • Chiang C.
        • et al.
        Association of the Centers for Medicare & Medicaid Services’ National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014.
        JAMA Intern Med. 2018; 178: 640-647
        • Ballard C.
        • Hanney M.L.
        • Theodoulou M.
        • et al.
        The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial.
        Lancet Neurol. 2009; 8: 151-157
        • Tun S.M.
        • Murman D.L.
        • Long H.L.
        • et al.
        Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease.
        Am J Geriatr Psychiatry. 2007; 15: 314-327
        • Chenoweth L.
        • Jessop T.
        • Harrison F.
        • et al.
        Critical contextual elements in facilitating and achieving success with a person-centred care intervention to support antipsychotic deprescribing for older people in long-term care.
        Biomed Res Int. 2018; 2018: 7148515
        • Conklin J.
        • Farrell B.
        • Ward N.
        • et al.
        Developmental evaluation as a strategy to enhance the uptake and use of deprescribing guidelines: Protocol for a multiple case study.
        Implement Sci. 2015; 10: 91